Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
BETINA study demonstrated promising efficacy and favorable tolerance in treating patients with mTNBC with bevacizumab with tislelizumab and nab-paclitaxel.
Authors
- Yanxia Shi (ORCID: https://orcid.org/0000-0002-5414-8049)
- Ditian Shu
- Fei Xu (ORCID: https://orcid.org/0000-0001-8543-6636)
- Qixiang Rong (ORCID: https://orcid.org/0000-0001-7719-4243)
- Riqing Huang (ORCID: https://orcid.org/0000-0003-3618-9311)
- Kuikui Jiang (ORCID: https://orcid.org/0000-0003-4498-8404)
- Meiting Chen (ORCID: https://orcid.org/0000-0002-7195-1300)
- Qi Sun (ORCID: https://orcid.org/0000-0002-4845-0049)
- Haifeng Li (ORCID: https://orcid.org/0000-0001-8541-279X)
- Wei Yang (ORCID: https://orcid.org/0000-0003-1973-5579)
- Xin An (ORCID: https://orcid.org/0009-0002-7544-1452)
- Cong Xue (ORCID: https://orcid.org/0009-0007-8702-8696)
- Jing Peng
- Xiujiao Shen
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial People's Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-011314
- Citations
- 9
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 9.41